Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Proceedings of the National Academy of Sciences of the United States of America|January 23, 1996
Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNPB Ghetti, P Piccardo, M G Spillantini, et al.
Nature Medicine|April 23, 2021
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K Choueiri, Todd M Bauer, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2024
Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 StudyTobias Else, Eric Jonasch, Othon Iliopoulos, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 19, 2023
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labelingDhananjay D Marathe, Petra M Jauslin, Huub Jan Kleijn, et al.
The Lancet. Oncology|September 16, 2024
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 studyOthon Iliopoulos, Ane B Iversen, Vivek Narayan, et al.
The Lancet. Oncology|January 5, 2025
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 studyToni K Choueiri, Jaime R Merchan, Robert Figlin, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 3, 2006
Elevated plasma homocysteine in acute stroke was not associated with severity and outcome: stronger association with small artery diseaseF Perini, E Galloni, I Bolgan, et al.
The New England Journal of Medicine|November 24, 2021
Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau DiseaseEric Jonasch, Frede Donskov, Othon Iliopoulos, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|May 18, 2007
Validation of AIDA Cefalee, a computer-assisted diagnosis database for the management of headache patientsR De Simone, G Coppola, A Ranieri, et al.
Pageof 14